BioSyent
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2476 Argentia Rd Ste 402, Mississauga, O...Phone Number
(905) 206-0013Website
www.biosyent.comRevenue
$30.4 MillionStock Symbol
RXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About BioSyent
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty/hospital and international business units.Explore more
BioSyent Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioSyent your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if BioSyent had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at BioSyent
Check out if BioSyent is spiking on competitors!
BioSyent, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on BioSyent recently announced quarterly report
Product Launch: Get notified when BioSyent launches new products
Funding: Get notified immidiatlly once BioSyent has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if BioSyent has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at BioSyent
Find 2 more new buyers
Compare Similar Companies to BioSyent
Compare insights from companies similar to BioSyent, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioSyent is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioSyent is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioSyent.
BioSyent financials insights
Gather financial insights about BioSyent, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Stock Offering
$6.8M
BioSyent Tech Stack
A closer look at the technologies used by BioSyent
Most Recent Scoops
Project
BioSyent has announced THYCONVI, a Health Canada-approved branded liquid levothyroxine product in the endocrinology category, designed for patients who cannot or prefer not to swallow oral dose medicine, including those with swallowing difficulties, oncology patients with oral mucositis, and pediatric patients.
Project
BioSyent has announced plans to launch a new indication for FeraMAX, the number one selling oral iron supplement in Canada, currently in late-stage development with an expected market launch in 2028.
Pharmaceuticals
Earnings
reported that its international pharma business had a solid quarter and a very strong year with over 300% growth.
Sales, Pharmaceuticals, Acquisitions
Earnings
reported that Q4 2025 represented the company's 62nd consecutive profitable quarter. The company became profitable in mid-year 2010 and has been consistently profitable since then.
Earnings, Finance
Award
Award, Pharmaceuticals
BioSyent News & Media
BioSyent to Present at Planet MicroCap Las Vegas
MISSISSAUGA, Ontario, June 15, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Las Vegas investor conference in Las Vegas, Nevada from June 16th to June 18th, 2026 at the Bellagio Hotel. Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person to attendees at the conference on Wednesday, June 17th at 4:00pm PDT.BioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)
MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.BioSyent says Oral Science acquisition added nearly $3M in March sales
BioSyent says its acquisition of Oral Science contributed nearly $3 million in sales during March as the company expands its oral health business in Canada.BioSyent Declares Second Quarter 2026 Dividend
MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on June 15, 2026, to shareholders of record at the close of business on May 29, 2026. This second quarter 2026 dividend compares to a first quarter dividend of $0.055 per common share. This dividend qualifies
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioSyent
Sign Up For FreeTo access detailed company insights
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty/hospital an... Read More
